Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Accreditations And Approvals
    • Good Laboratory Practice
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Investors » Announcements & Disclosures
  • Investors
     
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s
    • Investors Contact
    • Go green
    • IEPF

Announcements & Disclosures

  • 2020-21
  • 2019-20
  • 2018-19
  • 2017-18
  • 2016-17
  • 2015-16
  • 2014-15

Quarterly Announcements & Disclosures

  • Q1 Apr - Jun
  • Q2 Jul - Sep
  • Q3 Oct - Dec
  • Q4 Jan - Mar
Independent Directors Familiarisation Program during the year 2019-20
Notice of Board Meeting on 2nd June 2020
Related Party Disclosures for half year ended on 31st March 2020
Newspaper Advertisement of 15th AGM through VC/OAVM
Notice for the 15th Annual General Meeting
Notice of Board Meeting on 4th August 2020
Related Party Disclosures for half year ended on 30th September 2020
Notice of Board Meeting on 9th November 2020
Proceedings of 15th Annual General Meeting
Voting Results of 15th Annual General Meeting
Transcript of the 15th Annual General Meeting
Notice of Board Meeting on 8th February 2021

Quarterly Announcements & Disclosures

  • Q1 Apr - Jun
  • Q2 Jul - Sep
  • Q3 Oct - Dec
  • Q4 Jan - Mar
Notice of Board Meeting on 7th May 2019
Detail of Independent Directors Familiarisation Program 2018-19
Related Party Disclosures for half year ended on 31st March 2019.
Notice for the 14th Annual General Meeting
Notice of Board Meeting on 29th July 2019
Proceedings of 14th Annual General Meeting
Voting Results of 14th Annual General Meeting
Notice of Board Meeting on 4th November 2019
Related Party Disclosures for half year ended on 30th September 2019
Update on Taclantis®
Investor Presentation – Update on R&D Pipeline
Press Release – Audio Playback for Update on R&D Pipeline
Notice of Board Meeting on 31st January 2020
SPARC Receives Orphan Drug Designation from the USFDA for Phenobarbital for the Treatment of Patients with Neonatal Seizures
Resignation by Mr. Mark Simon as Independent Director of the Company
Update on TACLANTIS™ (Paclitaxel Injection Concentrate for Suspension) NDA

Quarterly Announcements & Disclosures

  • Q1 Apr - Jun
  • Q2 Jul - Sep
  • Q3 Oct - Dec
  • Q4 Jan - Mar
Details of Independent Directors familiarisation Program - 2017-18
Notice of Board Meeting on 8th May 2018
Notice for the 13th Annual General Meeting
Notice of Board Meeting on 30th July 2018
Revised Articles of Association proposed for shareholders approval at 13th Annual General Meeting
Proceedings of 13th Annual General Meeting
Voting Results of 13th Annual General Meeting
Allotment of 50,50,505 equity shares on conversion of Warrants
Notice of Board Meeting on 29th October 2018
Inter-se change in the shareholding of certain promoter group entities on account of Scheme of Amalgamation
Receipt of US FDA Approval of ELEPSIA ™ XR 1000mg and ELEPSIA ™ XR 1500mg
Allotment of 6060606 equity shares on conversion of warrants
Achievement of milestone - commercialisation of XELPROS ™
Shareholding Pattern - 11th January 2019 POST
Notice of Board Meeting on 4th February 2019
Receipt of Demand Order from the Office of Commissioner of GST & Central Excise
Return of Product Rights by partner for ELEPSIA ™ XR 1000/1500mg
Mandatory Dematerialization for Transfer of Securities

Quarterly Announcements & Disclosures

  • Q1 Apr - Jun
  • Q2 Jul - Sep
  • Q3 Oct - Dec
  • Q4 Jan - Mar
Details of Independent Directors familiarisation Program - 2016-17
Notice of Board Meeting on 5th May 2017
Outcome of Board Meeting held on 5th May 2017
Notice of EGM - 2nd June 2017
Notice for the 12th Annual General Meeting
Update on Elepsia XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg) NDA
Allotment of 151,51,515 warrants by the Company
Notice of Board Meeting on 5th August 2017
Annulment of Forfeiture 5th August 2017
Notice of Board Meeting on 27th October 2017
Allotment of Equity Shares - 15th December 2017
Notice of Board Meeting 29th January 2018

Quarterly Announcements & Disclosures

  • Q1 Apr - Jun
  • Q2 Jul - Sep
  • Q3 Oct - Dec
  • Q4 Jan - Mar
Notice for 11th Annual General Meeting 2015-16
Notice - Completion of dispatch & remote e-voting at 11th AGM
Notice of Board Meeting on 29th July 2016
Press Release - Update on NCE and NDDS Programs
Proceedings of the 11th Annual General Meeting held on 29th July 2016
Voting Results of 11th Annual General Meeting
Postal Ballot Notice and Form - August 2016
News Paper Notice - Postal Ballot 2016
Results of Postal Ballot 2016
Notice of Board Meeting on 28th October 2016
Update of XELPROS
Committee's of the Board
Notice of Board Meeting on 27th January 2017
Authorised KMP - Revised list January 2017
Receipt of IT Demand Notice
Indirect acquisition of controlling stake in the Company by Shanghvi Finance Pvt. Ltd.

Quarterly Announcements & Disclosures

  • Q1 Apr - Jun
  • Q2 Jul - Sep
  • Q3 Oct - Dec
  • Q4 Jan - Mar
Quarterly Corporate Governance Report for the quarter ended 31st March 2015
Notice of Annual General Meeting FY 2014-2015
Corporate Governance Report for the quarter ended 30th June 2015
Proceedings & outcome of 10th Annual General Meeting
Clarification on incorrect details regarding the Company in certain news articles
Quarterly Corporate Governance Report for the quarter ended 30th September 2015
Authorised KMP
Notice of Board Meeting 3rd February 2016

Quarterly Announcements & Disclosures

  • Q1 Apr - Jun
  • Q2 Jul - Sep
  • Q4 Jan - Mar
Notice of Board Meeting for Consideration of Audited financial results for the year ended 31-03-2014
Notice of Ninth Annual General Meeting for 2013-14 on 31st July 2014
Notice of Board Meeting for Consideration of Un-audited financial results for the Quarter ended 30-06-2014
Notice of Board Meeting for Consideration of Un-audited financial results for the Quarter ended 31-12-2014

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits